BCLI | Brainstorm Cell Therapeutics Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.2122 - 2.4499
52 Week Range	1.0500 - 11.85
Beta	1.15
Implied Volatility	248.36%
IV Rank	19.02%
Day's Volume	182,739
Average Volume	106,093
Shares Outstanding	5,703,430
Market Cap	13,003,820
Sector	Healthcare
Industry	Biotechnology
IPO Date	2003-10-07

Valuation
Profitability
Growth
Health
P/E Ratio	-0.66
Forward P/E Ratio	N/A
EPS	-3.45
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	29
Country	USA
Website	BCLI

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

BCLI's peers: PLX, CRVS, ALDX, GMDA, CKPT, HOWL, EWTX, DBTX, CELC, CCCC, LIFE, TRVI, CUE, ANTX, BCAB, PASG, HCWB, GBIO, GRI, CNTB, DAWN, TERN, XFOR, INZY, MREO

*Chart delayed

Analyzing fundamentals for BCLI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see BCLI Fundamentals page.

Watching at BCLI technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on BCLI Technicals page.